當(dāng)前位置：首頁(yè) > 新聞動(dòng)態(tài) > 行業(yè)新聞新冠肺炎“炎癥風(fēng)暴”是近期公眾關(guān)注的諸多熱點(diǎn)話題之一；所謂“炎癥風(fēng)暴”即全身炎癥反應(yīng)綜合征（SIRS），人體的炎癥因子，不僅可以殺掉病毒，也會(huì)給自身造成損害，某些新冠患者后期可能突然啟動(dòng)了一個(gè)“炎癥風(fēng)暴”，結(jié)果導(dǎo)致各個(gè)器官的功能衰竭。那么應(yīng)該如何應(yīng)對(duì)“炎癥風(fēng)暴”呢？中南大學(xué)湘雅醫(yī)學(xué)院林韶輝博士撰文“有效針對(duì)新冠肺炎的“炎癥風(fēng)暴”——Omega-3多不飽和脂肪酸”，表達(dá)了自己的一些觀點(diǎn)，或許會(huì)給大家一些思考和啟發(fā)。
一、新冠肺炎專家說(shuō)
1. 武漢金銀潭醫(yī)院：上海中山醫(yī)院重癥醫(yī)學(xué)科副主任鐘鳴醫(yī)生（2020年1月24到達(dá)武漢），2020年2月3日，南方人物周刊對(duì)鐘醫(yī)生進(jìn)行獨(dú)家專訪，提到救治初期，所面臨的困難之中，有的新冠患者后期可能突然啟動(dòng)了一個(gè)“炎癥風(fēng)暴”，這種炎癥風(fēng)暴導(dǎo)致了各個(gè)器官的功能衰竭，一旦進(jìn)入這個(gè)狀態(tài)，我們的治療很難把它拉回來(lái)。
2. 武漢大學(xué)中南醫(yī)院：《美國(guó)醫(yī)學(xué)會(huì)雜志》2月7日在線發(fā)布了武漢大學(xué)中南醫(yī)院重癥監(jiān)護(hù)室（ICU）主任彭志勇博士領(lǐng)銜的一項(xiàng)回顧性分析，研究團(tuán)隊(duì)認(rèn)為，新冠肺炎致死的三大主要機(jī)制：
中性粒細(xì)胞增多，與細(xì)胞因子風(fēng)暴有關(guān)；
D-二聚體升高反映凝血激活，提示持續(xù)的炎癥反應(yīng)；
血尿素升高提示急性腎損傷，這是感染、休克和缺氧的綜合結(jié)果。
3. 種種跡象表明，這些重癥患者中發(fā)生了不可逆轉(zhuǎn)的“炎癥風(fēng)暴”。而一旦患者發(fā)生“炎癥風(fēng)暴”，糖皮質(zhì)激素是對(duì)抗炎癥風(fēng)暴的武器之一，可以給免疫系統(tǒng)“滅火”，減輕機(jī)體損傷。不過(guò)，糖皮質(zhì)激素是一把“雙刃劍”。一方面它可以減輕炎癥反應(yīng)，有利于改善缺氧、呼吸窘迫癥狀；但長(zhǎng)期大劑量使用也可能引發(fā)諸多不良反應(yīng)。不少經(jīng)過(guò)大劑量激素治療的“非典”患者，都留下了如股骨頭壞死等嚴(yán)重后遺癥。
二、“炎癥風(fēng)暴”與Omega-3多不飽和脂肪酸
3. Omega-3 PUFA對(duì)抗炎癥反應(yīng)的作用機(jī)制
圖1. 長(zhǎng)鏈不飽和脂肪酸代謝示意圖
4. 多種文獻(xiàn)證明，為了減少患者還可能發(fā)生爆發(fā)性炎癥反應(yīng)，使用高純度的 Omega-3 PUFA制劑，可以減低炎癥風(fēng)暴的發(fā)生風(fēng)險(xiǎn)。具體表現(xiàn)
4.1 Omega-3 PUFA富集于細(xì)胞膜，參與炎癥反應(yīng)調(diào)控過(guò)程，減少炎性細(xì)胞產(chǎn)生促炎性細(xì)胞因子；
Omega-3 PUFA富集于細(xì)胞膜，提高細(xì)胞膜EPA和DHA脂肪酸的比例[11, 12]，影響胞內(nèi)信號(hào)傳導(dǎo)，抑制炎癥相關(guān)的轉(zhuǎn)錄因子NF-kappa B的轉(zhuǎn)錄活性[13, 14]，從而減少促炎性細(xì)胞因子TNF-alpha、IL-6 和IL-8等的表達(dá)[15]。
花生四烯酸類脂質(zhì)經(jīng)一系列酶催化產(chǎn)生促炎癥調(diào)節(jié)作用的前列腺素（PGE2）和白三烯B4等。這些促炎性介質(zhì)進(jìn)而可激活中性粒細(xì)胞、巨噬細(xì)胞，刺激炎癥細(xì)胞因子TNF-α、IL-1、IL-2、IL-8和干擾素（Interferon, IFN）等釋放增多。Omega-3和Omega-6兩類 PUFA競(jìng)爭(zhēng)相同的脂肪酸代謝酶（Elovl5和FADS2）系統(tǒng)[16-18]，從而干擾促炎性介質(zhì)的生成。
EPA和DHA經(jīng)代謝產(chǎn)生消散素（Resolvins）和保護(hù)素（Protections）。實(shí)驗(yàn)研究證實(shí)，消散素和保護(hù)素在關(guān)節(jié)炎[19]、結(jié)腸炎[20]、哮喘[21, 22]等多種炎性疾病中發(fā)揮重要的抗炎作用[23, 24] 。例如，resolvin E1，resolvin D1和protectin D1能抑制浸潤(rùn)性中性粒細(xì)胞的細(xì)胞遷移，從而減輕局部炎癥[24]。此外，resolvin D1和protectin D1還能抑制TNF-α and IL-1β的產(chǎn)生，從而減弱炎癥反應(yīng)[25, 26]。
5. Omega-3 PUFA緩解炎癥的具體臨床獲益
5.1 C反應(yīng)蛋白等炎癥指標(biāo)顯著下降，血紅蛋白和白細(xì)胞、血小板等細(xì)胞類群總量顯著上升。
表1. ICU患者使用Omega-3 PUFA帶來(lái)的生理指標(biāo)和臨床指標(biāo)獲益
5.2 敗血癥狀明顯下降，治療用抗生素使用時(shí)間縮短，全身炎癥反應(yīng)綜合征減少，器官功能障礙后遺癥發(fā)生率減少，死亡率下降；
美國(guó)田納西大學(xué)附屬醫(yī)院和西班牙多所醫(yī)院的臨床研究表明，對(duì)于重癥創(chuàng)傷患者和膿毒癥患者等ICU患者，每天1~3克Omega-3 PUFA營(yíng)養(yǎng)液可以有效降低菌血癥、敗血癥并發(fā)癥發(fā)生（下降14%[29]~35%[30]），明顯降低治療用抗生素使用時(shí)間和腹腔內(nèi)膿腫發(fā)生率[30]。而使用更高Omega-3 PUFA含量（4克以上）的營(yíng)養(yǎng)液后，創(chuàng)傷病人全身炎癥反應(yīng)綜合征發(fā)生人數(shù)顯著下降[27]；膿毒癥、敗血癥患者的器官功能障礙發(fā)生率減少達(dá)到43%[31]，死亡率顯著下降13.1%[29]~19.4%[31]。
表2. 創(chuàng)傷患者和敗血癥患者使用Omega-3 PUFA的臨床獲益
5.3 改善氧合狀態(tài)，減少呼吸機(jī)使用，縮短ICU監(jiān)護(hù)時(shí)間；
6.2 生物利用度高，保證體內(nèi)有效富集。
6.3 添加中鏈甘油三酯（MCTs），促進(jìn)Omega-3 PUFA快速細(xì)胞富集，為重癥患者的癥狀緩解贏得時(shí)間。添加MCT的Omega-3脂肪乳的體內(nèi)富集時(shí)間更短（術(shù)后第六天即檢測(cè)到病患血清磷脂和紅細(xì)胞細(xì)胞膜中的EPA和DHA顯著升高）[35]，激發(fā)免疫更強(qiáng)（第六天起外周血細(xì)胞釋放的白三烯B5含量已增長(zhǎng)約2倍）[36]；
參考文獻(xiàn)
1.Bone, R.C., C.J. Grodzin, and R.A. Balk, Sepsis: a new hypothesis for pathogenesis of the disease process. Chest, 1997. 112(1): p. 235-43.
2.Dobson, G.P., Addressing the Global Burden of Trauma in Major Surgery. Front Surg, 2015. 2: p. 43.
3.Binkowska, A.M., G. Michalak, and R. Slotwinski, Current views on the mechanisms of immune responses to trauma and infection. Cent Eur J Immunol, 2015. 40(2): p. 206-16.
4.Molfino, A., et al., Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both? Oxid Med Cell Longev, 2017. 2017: p. 5987082.
5.Alazawi, W., et al., Inflammatory and Immune Responses to Surgery and Their Clinical Impact. Ann Surg, 2016. 264(1): p. 73-80.
6.Hatakeyama, N. and N. Matsuda, Alert cell strategy: mechanisms of inflammatory response and organ protection. Curr Pharm Des, 2014. 20(36): p. 5766-78.
7.Matsuda, N., Alert cell strategy in SIRS-induced vasculitis: sepsis and endothelial cells. J Intensive Care, 2016. 4: p. 21.
8.Manson, J., C. Thiemermann, and K. Brohi, Trauma alarmins as activators of damage-induced inflammation. Br J Surg, 2012. 99 Suppl 1: p. 12-20.
9.Uddin, M. and B.D. Levy, Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res, 2011. 50(1): p. 75-88.
10.Barnig, C., N. Frossard, and B.D. Levy, Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther, 2018. 186: p. 98-113.
11.Walker, C.G., et al., The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions. Nutrients, 2015. 7(8): p. 6281-93.
12.Mayer, K., et al., Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med, 2003. 29(9): p. 1472-81.
13.Novak, T.E., et al., NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol, 2003. 284(1): p. L84-9.
14.Lo, C.J., et al., Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res, 1999. 82(2): p. 216-21.
15.Calder, P.C., Omega-3 fatty acids and inflammatory processes. Nutrients, 2010. 2(3): p. 355-74.
16.de Gomez Dumm, I.N. and R.R. Brenner, Oxidative desaturation of alpha-linoleic, linoleic, and stearic acids by human liver microsomes. Lipids, 1975. 10(6): p. 315-7.
17.Hagve, T.A. and B.O. Christophersen, Effect of dietary fats on arachidonic acid and eicosapentaenoic acid biosynthesis and conversion to C22 fatty acids in isolated rat liver cells. Biochim Biophys Acta, 1984. 796(2): p. 205-17.
18.Hagve, T.A. and B.O. Christophersen, Evidence for peroxisomal retroconversion of adrenic acid (22:4(n-6)) and docosahexaenoic acids (22:6(n-3)) in isolated liver cells. Biochim Biophys Acta, 1986. 875(2): p. 165-73.
19.Lima-Garcia, J.F., et al., The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol, 2011. 164(2): p. 278-93.
20.Arita, M., et al., Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A, 2005. 102(21): p. 7671-6.
21.Aoki, H., et al., Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun, 2008. 367(2): p. 509-15.
22.Haworth, O., et al., Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol, 2008. 9(8): p. 873-9.
23.Serhan, C.N., et al., Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J Physiol Pharmacol, 2000. 51(4 Pt 1): p. 643-54.
24.Serhan, C.N., et al., Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med, 2002. 196(8): p. 1025-37.
25.Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature, 2014. 510(7503): p. 92-101.
26.Serhan, C.N., N. Chiang, and T.E. Van Dyke, Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol, 2008. 8(5): p. 349-61.
27.Bastian, L., et al., [Clinical effects of supplemental enteral nutrition solution in severe polytrauma]. Unfallchirurg, 1998. 101(2): p. 105-14.
28.Al-Biltagi, M.A., et al., Beneficial Effects of Omega-3 Supplement to the Enteral Feeding in Children With Mild to Moderate Sepsis. J Intensive Care Med, 2017. 32(3): p. 212-217.
29.Galban, C., et al., An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med, 2000. 28(3): p. 643-8.
30.Kudsk, K.A., et al., A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications. Ann Surg, 1996. 224(4): p. 531-40; discussion 540-3.
31.Pontes-Arruda, A., A.M. Aragao, and J.D. Albuquerque, Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med, 2006. 34(9): p. 2325-33.
32.Atkinson, S., E. Sieffert, and D. Bihari, A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Guy's Hospital Intensive Care Group. Crit Care Med, 1998. 26(7): p. 1164-72.
33.Farquharson, A.L., et al., Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol, 2011. 108(6): p. 851-6.
34.Kemen, M., et al., Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients: an immunologic evaluation of Impact. Crit Care Med, 1995. 23(4): p. 652-9.
35.Senkal, M., et al., Supplementation of omega-3 fatty acids in parenteral nutrition beneficially alters phospholipid fatty acid pattern. JPEN J Parenter Enteral Nutr, 2007. 31(1): p. 12-7.
36.Koller, M., et al., Impact of omega-3 fatty acid enriched TPN on leukotriene synthesis by leukocytes after major surgery. Clin Nutr, 2003. 22(1): p. 59-64.
37.Senkal, M., et al., Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg, 1995. 161(2): p. 115-22.
38.Iwase, H., et al., Nutritional Effect of Oral Supplement Enriched in omega-3 Fatty Acids, Arginine, RNA on Immune Response and Leukocyte-platelet Aggregate Formation in Patients Undergoing Cardiac Surgery. Nutr Metab Insights, 2014. 7: p. 39-46.
39.Gianotti, L., et al., Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms. Arch Surg, 1997. 132(11): p. 1222-9; discussion 1229-30.
40.Schilling, J., et al., Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutions. Nutrition, 1996. 12(6): p. 423-9.
41.Daly, J.M., et al., Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery, 1992. 112(1): p. 56-67
公司郵箱：wlf-0471@163.com
銷售熱線：400-6758105
天貓店二維碼
萬(wàn)利福公眾號(hào)